Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1993 4
1994 2
1995 4
1996 2
1997 1
1998 2
1999 1
2000 1
2002 1
2010 1
2015 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization.
Banga J, Srinivasan D, Sun CC, Thompson CD, Milletti F, Huang KS, Hamilton S, Song S, Hoffman AF, Qin YG, Matta B, LaPan M, Guo Q, Lu G, Li D, Qian H, Bolin DR, Liang L, Wartchow C, Qiu J, Downing M, Narula S, Fotouhi N, DeMartino JA, Tan SL, Chen G, Barnes BJ. Banga J, et al. Among authors: bolin dr. Sci Adv. 2020 May 15;6(20):eaay1057. doi: 10.1126/sciadv.aay1057. eCollection 2020 May. Sci Adv. 2020. PMID: 32440537 Free PMC article.
Concepts and progress in the development of peptide mimetics.
Olson GL, Bolin DR, Bonner MP, Bös M, Cook CM, Fry DC, Graves BJ, Hatada M, Hill DE, Kahn M, et al. Olson GL, et al. Among authors: bolin dr. J Med Chem. 1993 Oct 15;36(21):3039-49. doi: 10.1021/jm00073a001. J Med Chem. 1993. PMID: 8230089 Review. No abstract available.
Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules.
Falcioni F, Ito K, Vidovic D, Belunis C, Campbell R, Berthel SJ, Bolin DR, Gillespie PB, Huby N, Olson GL, Sarabu R, Guenot J, Madison V, Hammer J, Sinigaglia F, Steinmetz M, Nagy ZA. Falcioni F, et al. Among authors: bolin dr. Nat Biotechnol. 1999 Jun;17(6):562-7. doi: 10.1038/9865. Nat Biotechnol. 1999. PMID: 10385320
Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors.
de Vicente J, Tivitmahaisoon P, Berry P, Bolin DR, Carvajal D, He W, Huang KS, Janson C, Liang L, Lukacs C, Petersen A, Qian H, Yi L, Zhuang Y, Hermann JC. de Vicente J, et al. Among authors: bolin dr. ACS Med Chem Lett. 2015 Aug 4;6(9):1019-24. doi: 10.1021/acsmedchemlett.5b00251. eCollection 2015 Sep 10. ACS Med Chem Lett. 2015. PMID: 26396691 Free PMC article.
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.
Bolin DR, Swain AL, Sarabu R, Berthel SJ, Gillespie P, Huby NJ, Makofske R, Orzechowski L, Perrotta A, Toth K, Cooper JP, Jiang N, Falcioni F, Campbell R, Cox D, Gaizband D, Belunis CJ, Vidovic D, Ito K, Crowther R, Kammlott U, Zhang X, Palermo R, Weber D, Guenot J, Nagy Z, Olson GL. Bolin DR, et al. J Med Chem. 2000 Jun 1;43(11):2135-48. doi: 10.1021/jm000034h. J Med Chem. 2000. PMID: 10841792
24 results